News
Research Findings Demonstrate miRagen Therapeutics’ Synthetic microRNA-29 Mimic (promiR-29) Reverses Pulmonary Fibrosis
BOULDER, CO, USA I September 22, 2014 I miRagen Therapeutics, Inc., a biopharmaceutical company developing innovative microRNA-based therapeutics, announced today that findings from a research collaboration between the Company and Yale University have demonstrated that promiR-29 reversed fibrosis in a mouse model of pulmonary fibrosis. These findings were published in the journal EMBO Molecular Medicine http://onlinelibrary.wiley.com/doi/10.15252/emmm.201303604/full on September 19, 2014.
Source: PipelineReview.com